BERKELEY, Calif., Jan. 19, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today provided a summary of its priorities for 2010 and accomplishments during 2009.
-snip-
2009 Accomplishments
XOMA 052 and Proprietary Pipeline
-snip-
Biodefense
- Advanced XOMA 3AB, an anti-botulism antibody, into pre-IND studies.
 - Obtained $3.9 million in new government contracts for the development of antibodies to the H1N1/H5N1 and SARS viruses.
 - Presented new XOMA technology for the development and evaluation of multiple antibody “cocktail� formulations.
-snip-
XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of about 200 employees at its Berkeley, California location. For more information, please visit http://www.xoma.com.
No comments:
Post a Comment